For Industry

Available technologies

Clear search
Novel phage/AAV delivery vector for gene therapy, medical imaging and vaccine delivery

The present invention relates to a novel DNA delivery vector for targeted gene therapy, medical imaging and vaccination with increased efficacy over existing technologies. The platform comprises a phagemid hybrid with phage and recombinant adeno-associated virus (AAV) components.

Novel large-scale method of production of AAVs

A novel viral delivery vector with scope for more cost-effective commercial production over existing technologies. The platform comprises a phagemid hybrid with recombinant adeno-associated virus (AAV) components.

Novel multifunctional bacteriophages

Researchers at Imperial College London have developed two novel modifications of bacteriophages to significantly improve their efficacy as vectors for targeted gene therapy, and exploit their advantages over eukaryotic viral vectors.

Novel protein fragment of von Willebrand’s factor for treating VWD and haemophilia A

Novel truncated fragments of von Willebrand factor (VWF) engineered by a team at Imperial College London.

Subscribe for Licensing Opportunities updates
Keep up to date with new technologies and licensing opportunities coming out of Imperial College London